Artelo Biosciences ARTL
NASDAQ ARTL
$5.98 -0.21 (-3.39%)
At close: Sep 9, 2026 · 4:00 PM EDT

Artelo Biosciences (ARTL) Non Operating Interest Expenses (2017 - 2025)

Artelo Biosciences' (ARTL) quarterly Non Operating Interest Expenses came in at $11000.0 in Q4 2025, down 90.09% quarter-over-quarter from $111000.0 in Q3 2025.

Analysis

Artelo Biosciences (ARTL) Non Operating Interest Expenses (2017 - 2025) Analysis & Trends

Artelo Biosciences (ARTL) has reported Non Operating Interest Expenses for 3 consecutive years, with $11000.0 the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $11000.0 in Q4 2025; TTM through Dec 2025 was $194000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $194000.0, changed N/A from the prior year.
  • Non Operating Interest Expenses was $11000.0 for Q4 2025 at Artelo Biosciences, down from $111000.0 in the prior quarter.
  • Over five years, Non Operating Interest Expenses peaked at $111000.0 in Q3 2025 and troughed at $5000.0 in Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Artelo Biosciences 120,353.04 -479,646.96 - 11,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 11,000.00
Sep 30, 2025 111,000.00
Jun 30, 2025 72,000.00
Sep 30, 2022 5,000.00
Aug 31, 2017 177.00
May 31, 2017 907.00
Feb 28, 2017 1,016.00